CHAN; Andrew C.
Patent Applications and Registrations
Patent applications and USPTO patent grants for CHAN; Andrew C..The latest application filed is for "immunoglobulin variants and uses thereof".
- CHAN; Andrew C. - Menlo Park CA
- Chan; Andrew C. - St. Louis MO
| Patent | Date |
|---|---|
| Immunoglobulin Variants And Uses Thereof App 20220002430 - ADAMS; Camellia W. ; et al. | 2022-01-06 |
| Immunoglobulin Variants And Uses Thereof App 20190071511 - ADAMS; Camellia W. ; et al. | 2019-03-07 |
| Composition and methods for the diagnosis of immune related diseases involving the PRO52254 polypeptide Grant RE46,816 - Baldwin , et al. May 1, 2 | 2018-05-01 |
| Composition and methods for the diagnosis of immune related diseases involving the PRO52254 polypeptide Grant RE46,805 - Baldwin , et al. April 24, 2 | 2018-04-24 |
| Composition and methods for the diagnosis of immune related diseases involving the PRO52254 polypeptide Grant RE46,534 - Baldwin , et al. September 5, 2 | 2017-09-05 |
| Immunoglobulin Variants And Uses Thereof App 20170158773 - ADAMS; Camellia W. ; et al. | 2017-06-08 |
| Immunoglobulin Variants And Uses Thereof App 20140154242 - ADAMS; Camellia W. ; et al. | 2014-06-05 |
| Immunoglobulin variants and uses thereof Grant 8,562,992 - Adams , et al. October 22, 2 | 2013-10-22 |
| Immunoglobulin variants and uses thereof Grant 7,799,900 - Adams , et al. September 21, 2 | 2010-09-21 |
| Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor Grant 7,662,926 - Chan , et al. February 16, 2 | 2010-02-16 |
| Anti-FC-gamma RIIB receptor antibody and uses therefor Grant 7,655,229 - Chan , et al. February 2, 2 | 2010-02-02 |
| Novel Composition And Methods For The Treatment Of Immune Related Diseases App 20090181024 - Baldwin; Daryl T. ; et al. | 2009-07-16 |
| Immunoglobulin Variants And Uses Thereof App 20090155257 - ADAMS; CAMELLIA W. ; et al. | 2009-06-18 |
| Anti-fc-gamma Riib Receptor Antibody And Uses Therefor App 20090087428 - Chan; Andrew C. ; et al. | 2009-04-02 |
| Treatment Method App 20080299117 - Barron; Hal V. ; et al. | 2008-12-04 |
| Treatment Method App 20080095771 - Barron; Hal V. ; et al. | 2008-04-24 |
| Method for Augmenting B Cell Depletion App 20080075719 - Chan; Andrew C. ; et al. | 2008-03-27 |
| Anti-FC-gamma RIIB receptor antibody and uses therefor App 20070253948 - Chan; Andrew C. ; et al. | 2007-11-01 |
| Treatment method App 20060188495 - Barron; Hal V. ; et al. | 2006-08-24 |
| Anti-Fc-gamma RIIB receptor antibody and uses therefor App 20060073142 - Chan; Andrew C. ; et al. | 2006-04-06 |
| Immunoglobulin variants and uses thereof App 20060034835 - Adams; Camellia W. ; et al. | 2006-02-16 |
| Immunoglobulin variants and uses thereof App 20060024300 - Adams; Camellia W. ; et al. | 2006-02-02 |
| Method for augmenting B cell depletion App 20050276803 - Chan, Andrew C. ; et al. | 2005-12-15 |
| Novel composition and methods for the treatment of immune related diseases App 20040121370 - Baldwin, Daryl T. ; et al. | 2004-06-24 |
| BLNK proteins Grant 6,638,724 - Chan , et al. October 28, 2 | 2003-10-28 |
| NCAGE Code | 4FSS2 | CHAN, ANDREW C |
| CAGE Code | 4FSS2 | CHAN, ANDREW C |
| DUNS | 780434028 | CHAN, ANDREW C |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 